KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biogen (BIIB) Other Operating Expenses (2016 - 2026)

Biogen has reported Other Operating Expenses over the past 18 years, most recently at -$19.7 million for Q1 2026.

  • For Q1 2026, Other Operating Expenses rose 71.2% year-over-year to -$19.7 million; the TTM value through Mar 2026 reached -$53.8 million, down 2141.67%, while the annual FY2024 figure was -$27.7 million, N/A changed from the prior year.
  • Other Operating Expenses for Q1 2026 was -$19.7 million at Biogen, up from -$34.1 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $428.6 million in Q2 2022 and troughed at -$300.0 million in Q3 2023.
  • A 5-year average of $5.8 million and a median of -$17.2 million in 2024 define the central range for Other Operating Expenses.
  • Biggest five-year swings in Other Operating Expenses: surged 344.61% in 2022 and later crashed 1077.46% in 2023.
  • Year by year, Other Operating Expenses stood at -$12.2 million in 2022, then tumbled by 2359.02% to -$300.0 million in 2023, then soared by 155.33% to $166.0 million in 2024, then crashed by 120.54% to -$34.1 million in 2025, then soared by 42.23% to -$19.7 million in 2026.
  • Business Quant data shows Other Operating Expenses for BIIB at -$19.7 million in Q1 2026, -$34.1 million in Q3 2025, and -$68.4 million in Q1 2025.